Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097697 | 0.93 | EPHX2 (0.53) | AVPR1BEPHX2 | |
| SCHEMBL10249267 | 0.89 | MET (0.47) | METTLR9TLR7HRH3 | |
| SCHEMBL10096333 | 0.88 | MET (0.44) | METTLR9AVPR1BEPHX2AURKA | |
| SCHEMBL10249321 | 0.88 | MET (0.47) | METTLR9HRH3 | |
| SCHEMBL10097493 | 0.86 | EPHX2 (0.51) | EPHX2AURKAAURKB | |
| SCHEMBL10097406 | 0.86 | EPHX2 (0.50) | EPHX2 | |
| SCHEMBL10097486 | 0.84 | EPHX2 (0.51) | EPHX2AURKAAURKB | |
| SCHEMBL10252373 | 0.84 | MTNR1B (0.48) | MAPT | |
| SCHEMBL10253105 | 0.84 | MET (0.41) | METTLR9EPHX2 | |
| SCHEMBL10249337 | 0.83 | EPHX2 (0.43) | METTLR9AVPR1BEPHX2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MET 1695/4885TLR9 3051/4885AVPR1B 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.